has been genetically linked to multiple myeloma for more than 15 years, drug
discovery efforts against the target have lagged behind other histone
methyltransferases including DOT1L
Now, a Novartis Institutes for BioMedical Research and
Institute of MIT and Harvard collaboration and an
independent Northwestern University team have identified activating mutations in NSD2
that drive a subset of leukemias,1,2 and a second Novartis team has
made the best case to date that inhibiting the protein could help treat MM.3
A separate collaboration between the
Broad Institute and NIBR, as well as an independent team from the Northwestern University Feinberg School of Medicine, have bolstered the case for targeting NSD2 by
uncovering a second genetically defined cancer driven by its activity.1
Although the evidence that inhibiting
NSD2 could have therapeutic benefit continues to build, the protein is still a
Cain, C. SciBX 6(39); doi:10.1038/scibx.2013.1083
Published online Oct. 10, 2013
1. Jaffe, J.D. et al.
Nat. Genet.; published online Sept. 29, 2013; doi:10.1038/ng.2777
Contact: Frank Stegmeier, Novartis Institutes for Biomedical Research,
Contact: Levi A. Garraway, Broad Institute of MIT and Harvard,
2. Oyer, J.A. et al.
Leukemia; published online July 26, 2013; doi:10.1038/leu.2013.204
Contact: Relja Popovic, Northwestern University, Chicago, Ill.
Contact: Jonathan D. Licht, same affiliation as above
3. Huang, Z. et al.
Cancer Res.; published online Aug. 26, 2013;
Contact: Min Hu, Novartis Institutes for BioMedical Research, Shanghai,
4. Asangani, I.A. et
al. Mol. Cell 49, 80-93 (2013)
5. Martinez-Garcia, E. et
al. Blood 117, 211-220 (2011)
6. Kotz, J. SciBX 6(15);
AND INSTITUTIONS MENTIONED
Astex Pharmaceuticals Inc. (NASDAQ:ASTX), Dublin, Calif.
Institute of MIT and Harvard, Cambridge, Mass.
Cancer Research Technology Ltd., London, U.K.
Celgene Corp. (NASDAQ:CELG), Summit, N.J.
Dana-Farber Cancer Institute, Boston, Mass.
Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan
Epizyme Inc. (NASDAQ:EPZM), Cambridge, Mass.
Harvard Medical School, Boston, Mass.
The Institute of Cancer Research, Sutton, U.K.
Northwestern University, Evanston, Ill.
Northwestern University Feinberg School of Medicine, Chicago, Ill.
Novartis Institutes for BioMedical Research, Boston, Mass.
Robert H. Lurie Comprehensive Cancer Center of Northwestern
OncoFusion Therapeutics Inc., Ann Arbor, Mich.
Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan
University of Michigan Medical School, Ann Arbor, Mich.